For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Meiji, Fujirebio Terminate Joint Sales Agreement
April 11, 2011
- Korosho Calls For Restraint in Use of EN Products Due to Shortage of Ensure
April 11, 2011
- Looking Back Over a Hectic Week for Vaccines
April 4, 2011
- Prazaxa to Mainly Target CV Specialists, Neurologists: NBI
April 4, 2011
- NIBIO to Promote Development of Next-generation Adjuvants
April 4, 2011
- New Drugs May Be Approved 1 Month Earlier from April
April 4, 2011
- Kitasato Daiichi Sankyo Vaccine Co., Ltd. Inaugurated
April 4, 2011
- Restrictions on Ex-company Employees of PMDA to Remain for Now
April 4, 2011
- Tokyo District Court Holds Both Gov't, AZ Responsible in Iressa Affair
April 4, 2011
- Takeda Applies for Novel ARB Azilsartan in Japan
April 4, 2011
- ASKA Resumes Production, Shipment of Thyradin-S Tablets
April 4, 2011
- Daiichi Sankyo's Direct Xa Inhibitor Rixiana Recommended for Approval by PAC
April 4, 2011
- Damage at Fukushima Plant to Affect 3 Brands: Ajinomoto Pharm.
April 4, 2011
- Eisai Announces Approval of Halaven in Europe
April 4, 2011
- Daiichi Sankyo Resumes Production at Some Facilities
April 4, 2011
- Fingolimod Approved for MS in Europe: Novartis
April 4, 2011
- Shipments of Ensure to Resume in Late May: Abbott Japan
April 4, 2011
- CHMP to Assess Benefit-Risk Balance of Pioglitazone
April 4, 2011
- Asahi Kasei Licenses XIAFLEX from Auxilium
April 4, 2011
- MREAC Calls For “Consideration”in Post-disaster MR Activities
April 4, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…